T. Rowe Price Associates’s Icosavax, Inc. Common Stock ICVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-3,342,470
Closed -$19.2M – 3058
2022
Q2
$19.2M Buy
3,342,470
+1,506,613
+82% +$11.8M ﹤0.01% 1179
2022
Q1
$12.9M Buy
1,835,857
+237,305
+15% +$3.73M ﹤0.01% 1329
2021
Q4
$36.6M Buy
1,598,552
+246,423
+18% +$6.36M ﹤0.01% 1109
2021
Q3
$40M Buy
+1,352,129
New +$45.8M ﹤0.01% 1096

Other funds holding ICVX

T. Rowe Price Associates's ICVX Position: Q3 2022 in Review

T. Rowe Price Associates sold out of Icosavax, Inc. Common Stock (ICVX) in Q3 2022, closing a stake of 3,342,470 shares — an estimated $19.2M sold.

T. Rowe Price Associates first reported a position in ICVX in Q3 2021 and held it in 4 quarters. The position peaked at $40M in Q3 2021. 73 funds tracked by Wall St. Rank hold ICVX as of Q3 2022.

  • T. Rowe Price Associates reported no remaining Icosavax, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 3,342,470 Icosavax, Inc. Common Stock shares in Q3 2022, an estimated $19.2M.
  • T. Rowe Price Associates first reported a position in Icosavax, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
  • T. Rowe Price Associates's Icosavax, Inc. Common Stock position peaked at $40M in Q3 2021.
  • 73 funds tracked by Wall St. Rank held Icosavax, Inc. Common Stock as of Q3 2022.

Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.